Studies have shown that T2DM patients exhibit a greater FAI of the pericoronary than non-T2DM patients do [33, 34], with particularly heightened FAI in those lacking glycemic control interventions or those with poorly controlled T2DM [34]
Many modern treatment options for type 2 diabetes, such as glucagon-like peptide-1 (GLP-1) receptor agonists, take a holistic approach, with substantial reductions in glycated hemoglobin (HbA1c) accompanied by benefits in blood pressure, serum lipid levels and body weight, and low risk of hypoglycemia [1]
Palmieri, F
The net effect is a half-life of approximately 2030 hours compared to the 1215 minutes of free native IGF-1, and a substantially elevated free peptide fraction that is available for receptor engagement
Reduced desire for alcohol use has been reported among patients taking GLP-1 receptor agonists or dual-agonists for the treatment of obesity [134]
However may also vary depending on the unique requirements of the pharmaceutical company you want to accomplish with
